

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 23, 2026

ORCHESTRA BIOMED HOLDINGS, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-39421
(Commission
File Number)

92-2038755
(IRS Employer
Identification No.)

150 Union Square Drive
New Hope, Pennsylvania 18938
(Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: (215) 862-5797

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value \$0.0001 per share	OBIO	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 23, 2026, Orchestra BioMed Holdings, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). A total of 59,880,715 shares of the Company’s common stock, par value \$0.0001 per share (“Common Stock”), were entitled to vote as of April 28, 2026, the record date for the Annual Meeting. There were 49,053,298 shares of Common Stock represented at the Annual Meeting, at which the Company’s stockholders were asked to vote on five proposals, each of which is described in more detail in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 29, 2026 (the “Proxy Statement”). Set forth below are the matters acted upon by the Company’s stockholders, and the final voting results of each such proposal.

Proposal No. 1: Election of Directors

Votes regarding the election of the three Class III director nominees were as follows:

Director Name	Votes For	Votes Withheld	Broker Non-Votes
David P. Hochman	39,724,691	97,018	9,231,589
Darren R. Sherman	39,544,240	277,469	9,231,589
Eric S. Fain	37,810,358	2,011,351	9,231,589

Based on the votes set forth above, the Company’s stockholders elected each of the three nominees set forth above to serve as a Class III director of the Company until the Company’s 2029 annual meeting of stockholders and until such director’s respective successor is duly elected and qualified.

Proposal No. 2: Ratification of Appointment of Independent Registered Public Accounting Firm

The proposal to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026 (the “Auditor Ratification Proposal”), received the following votes:

Votes For	Votes Against	Abstentions	Broker Non-Votes
49,039,578	13,692	28	-

Based on the votes set forth above, the Auditor Ratification Proposal was approved.

Proposal No. 3: Approval of the Orchestra BioMed Holdings, Inc. 2026 Employee Stock Purchase Plan

The proposal to approve the Orchestra BioMed Holdings, Inc. 2026 Equity Incentive Plan (the “ESPP Proposal”) received the following votes:

Votes For	Votes Against	Abstentions	Broker Non-Votes
39,639,592	150,243	31,874	9,231,589

Based on the votes set forth above, the ESPP Proposal was approved.

Proposal No. 4: Advisory, Non-Binding Vote on the Compensation of the Company’s Named Executive Officers

The advisory (non-binding) vote on the compensation of the Company’s named executive officers (the “NEOs”), as set forth in the Proxy Statement, received the following votes:

Votes For	Votes Against	Abstentions	Broker Non-Votes
37,975,986	1,778,200	67,523	9,231,589

Based on the votes set forth above, the Company's stockholders approved, on an advisory basis, the compensation of the NEOs.

Proposal No. 5: Advisory, Non-Binding Vote on the Frequency of the Vote on the Compensation of the Company's NEOs

The advisory (non-binding) vote on frequency of votes on the compensation of the NEOs at either 1 year, 2 years or 3 years, as set forth in the Proxy Statement, received the following votes:

1 Year	2 Years	3 Years	Abstain
38,995,022	25,675	791,227	9,785

Stockholders indicated, on an advisory basis, that they preferred that there be an advisory vote on the compensation of the NEOs every "1 Year". In light of the recommendation of the board of directors of the Company that future "say-on-pay" votes occur every "1 Year" and the results of the stockholder vote on Proposal No. 5, the Company intends to submit to its stockholders a non-binding advisory vote on the compensation of the NEOs at every annual meeting of stockholders until the next required advisory vote on the frequency of stockholder votes on the compensation of the NEOs, which is expected to occur in 2032.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ORCHESTRA BIOMED HOLDINGS, INC.

By: /s/ Andrew Taylor

Name: Andrew Taylor

Title: Chief Financial Officer

Date: June 23, 2026
